NCT05285137View on ClinicalTrials.gov

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

October 27, 2023

Study Completion Date

October 27, 2023

Conditions
Healthy
Interventions
COMBINATION_PRODUCT

CD388 Injection

CD388 liquid for injection

DRUG

Saline placebo

Sterile normal saline for injection

Trial Locations (1)

66212

Altasciences Clinical Kansas, Inc., Overland Park

Sponsors

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

Cidara Therapeutics Inc.

INDUSTRY

NCT05285137 - Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects | Biotech Hunter | Biotech Hunter